CardioGenesis gets $2 million credit line

9 August 2001

CardioGenesis Corp has announced the establishment of a $2 million lineof credit with Pacific Business Funding, a division of Cupertino National Bank, which expires in August 2002. The funds will be used to finance working capital, future development and general corporate purposes.

CardioGenesis' chief executive, Michael Quinn, said the company has "a strong suite of products and services, and a portfolio of patents and intellectual property that we believe will serve as the platform for us to continue to grow." He added that "it is appropriate to begin a commercial banking relationship at this point, both to add some leverage for the benefit of the shareholders, and to make working capital easily available should it be needed."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight